Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma

Authors: Can Shi, Zhenyu Zhang

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

Increasing evidences have revealed that microRNAs regulate various biological processes. However, the roles of miR-761 have not been investigated in ovarian cancer. Here, we found that miR-761 expression was significantly lower in ovarian cancer tissues than in their paired noncancerous tissues. Further study revealed that miR-761 overexpression inhibited the ovarian cancer cell proliferation and invasion. Mechanistically, we demonstrated that the oncogenic properties of miR-761 in ovarian cancer were mediated in part by regulating MSI1 expression. miR-761 and MSI1 are inversely expressed in ovarian cancer tissues. In conclusion, we demonstrated that miR-761 repressed ovarian cancer proliferation and invasion by targeting MSI1.
Literature
1.
Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46:436–46.CrossRefPubMed
2.
Dong Z, Yang L, Lai D. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression. Cell Prolif. 2013;46:425–35.CrossRefPubMed
3.
Eligar SM, Pujari R, Swamy BM, Shastry P, Inamdar SR. Sclerotium rolfsii lectin inhibits proliferation and induces apoptosis in human ovarian cancer cell line PA-1. Cell Prolif. 2012;45:397–403.CrossRefPubMed
4.
Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One. 2012;7:e34546.CrossRefPubMedPubMedCentral
5.
Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014;5:10816–29.CrossRefPubMedPubMedCentral
6.
Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Rep. 2012;5:1277–80.PubMed
7.
Wang L, Wang B, Fang M, Guo F, Cui M. Identification of microRNAs and target genes involved in serous ovarian carcinoma and their influence on survival. Eur J Gynaecol Oncol. 2014;35:655–61.PubMed
8.
Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
9.
Hirata Y, Murai N, Yanaihara N, Saito M, Urashima M, Murakami Y, et al. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer. 2014;14:799.CrossRefPubMedPubMedCentral
10.
Cui J, Eldredge JB, Xu Y, Puett D. MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS One. 2011;6:e21730.CrossRefPubMedPubMedCentral
11.
Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3501–8.CrossRef
12.
Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011;15:1593–602.CrossRefPubMedPubMedCentral
13.
Liu N, Zhou C, Zhao J, Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Investig. 2012;30:577–82.CrossRef
14.
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18:43–54.
15.
Yu X, Li Z, Liu J. Mirnas in primary cutaneous lymphomas. Cell Prolif. 2015.
16.
Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.PubMed
17.
Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48:1–6.CrossRefPubMed
18.
Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013;4:665–76.CrossRefPubMedPubMedCentral
19.
Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4:346–61.CrossRefPubMedPubMedCentral
20.
Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3:44–57.PubMedPubMedCentral
21.
Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y, et al. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One. 2012;7:e39102.CrossRefPubMedPubMedCentral
22.
Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One. 2012;7:e33778.CrossRefPubMedPubMedCentral
23.
Du B, Wang Z, Zhang X, Feng S, Wang G, He J, et al. MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One. 2014;9:e88022.CrossRefPubMedPubMedCentral
24.
Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology. 2014;60:872–83.CrossRefPubMedPubMedCentral
25.
Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015.
26.
Li Z, Yu X, Shen J, Jiang Y. Microrna dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015.
27.
Hecker N, Stephan C, Mollenkopf HJ, Jung K, Preissner R, Meyer HA. A new algorithm for integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. PLoS One. 2013;8:e64543.CrossRefPubMedPubMedCentral
28.
Long B, Wang K, Li N, Murtaza I, Xiao JY, Fan YY, et al. miR-761 regulates the mitochondrial network by targeting mitochondrial fission factor. Free Radic Biol Med. 2013;65:371–9.CrossRefPubMedPubMedCentral
29.
Cohen JE, Lee PR, Fields RD. Systematic identification of 3′-UTR regulatory elements in activity-dependent mRNA stability in hippocampal neurons. Philosophical Trans R Soc Lond B Biol Sci. 2014;369.
30.
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179.CrossRefPubMedPubMedCentral
31.
Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, Tewari M, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer. 2010;49:577–84.PubMedPubMedCentral
32.
Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, et al. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2009;19:641–7.CrossRef
33.
Tang H, Yao L, Tao X, Yu Y, Chen M, Zhang R, et al. MiR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting tln1. Int J Mol Med. 2013;32:381–8.PubMed
34.
Gao C, Han C, Yu Q, Guan Y, Li N, Zhou J, et al. Downregulation of Msi1 suppresses the growth of human colon cancer by targeting p21cip1. Int J Oncol. 2015;46:732–40.PubMed
35.
Liu X, Yang WT, Zheng PS. Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas. Oncotarget. 2014;5:10870–85.CrossRefPubMedPubMedCentral
36.
Gioia U, Di Carlo V, Caramanica P, Toselli C, Cinquino A, Marchioni M, et al. miR-23a and miR-125b regulate neural stem/progenitor cell proliferation by targeting Musashi1. RNA Biol. 2014;11:1105–12.CrossRefPubMedPubMedCentral
37.
Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells. 2014;32:135–44.CrossRefPubMedPubMedCentral
38.
Li D, Peng X, Yan D, Tang H, Huang F, Yang Y, et al. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann Surg Oncol. 2011;18:2074–83.CrossRefPubMed
39.
Vo DT, Subramaniam D, Remke M, Burton TL, Uren PJ, Gelfond JA, et al. The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol. 2012;181:1762–72.CrossRefPubMedPubMedCentral
40.
Vo DT, Abdelmohsen K, Martindale JL, Qiao M, Tominaga K, Burton TL, et al. The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res MCR. 2012;10:143–55.CrossRefPubMed
41.
Kuang RG, Kuang Y, Luo QF, Zhou CJ, Ji R, Wang JW. Expression and significance of Musashi-1 in gastric cancer and precancerous lesions. World J Gastroenterol WJG. 2013;19:6637–44.CrossRefPubMed
Metadata
Title
miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma
Authors
Can Shi
Zhenyu Zhang
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4377-z

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue

Original Article

Function analysis of rs9589207 polymorphism in miR-92a in gastric cancer

Original Article

HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)

Original Article

The protective role of the −1306C>T functional polymorphism in matrix metalloproteinase-2 gene is associated with cervical cancer: implication of human papillomavirus infection

Original Article

Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3′-oxime upon ovarian cancer cells

Original Article

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection

Original Article

Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits